Anthony Y. Sun - Mar 1, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Anthony Y. Sun
Stock symbol
ZNTL
Transactions as of
Mar 1, 2022
Transactions value $
-$1,046,649
Form type
4
Date filed
3/3/2022, 04:11 PM
Previous filing
Feb 14, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$436K -8.77K -0.72% $49.74 1.21M Mar 1, 2022 Direct F1, F2
transaction ZNTL Common Stock Sale -$85.1K -1.7K -0.14% $50.05 1.21M Mar 1, 2022 Direct F1, F3
transaction ZNTL Common Stock Sale -$490K -9.77K -0.81% $50.11 1.2M Mar 2, 2022 Direct F1, F4
transaction ZNTL Common Stock Sale -$35.6K -700 -0.06% $50.91 1.2M Mar 2, 2022 Direct F1, F5
holding ZNTL Common Stock 104K Mar 1, 2022 By Spouse
holding ZNTL Common Stock 974K Mar 1, 2022 By Essex Group International, LLC
holding ZNTL Common Stock 214K Mar 1, 2022 By Hao Bao Zi Trust LLC F6
holding ZNTL Common Stock 125K Mar 1, 2022 By Hao Jiao Zi Trust LLC F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.97 to $49.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.98 to $50.48. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.54 to $50.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.55 to $51.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
F7 Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.